首发精神分裂症患者血清β2微球蛋白的变化

Changes of β2 -microglobulin in patients with first episode schizophrenia

目的探讨精神分裂症患者血清p。微球蛋白（β2-MG）的变化及其临床意义。方法随机选取60例精神分裂症患者为研究组，60名健康人为对照组，在基线测定两组人群血清B2-MG水平，并应用阳性与阴性症状量表（PANSS）评定精神分裂症患者的精神症状。结果研究组血清β2-MG水平较对照组明显升高，差异有统计学意义（P〈0．05）；研究组血清β2-MG水平与PANSS总分（r=0．477，P〈0．001）、阴性分（r=0．422，P=0．001）和一般精神病理分（r=0．391，P=0．002）呈正相关，与阳性分无相关性（r=0．107，P：0．418）。结论血清β2-MG在精神分裂症的发病过程中可能起到重要作用，其浓度可作为评定精神分裂症患者免疫功能的指标之一。

Objective To explore the changes and clinical significance of β2-microglobulin β2- MG） in patients with first episode schizophrenia. Methods β2-MG was examined in schizophrenia pa- tients （n = 60） and healthy controls （n = 60）. PANSS was used to assess the clinical symptoms in schizophrenia patients. Results Serum β2- MG was significantly higher in schizophrenia patients than healthy con- trois （P 〈 0.05） there was a significant positive correlation between β2 - MG level and PANSS score （r = 0. 477, P 〈 0. 001）, negative score （r = 0. 422, P = 0. 001） and general pathology score （r = 0.391, P = 0. 002） ; there was no correlation with the positive scores （r = 0. 107 ,P = 0, 418）. Conclusions β2-MG may have a potential role in the pathogenesis of schizophrenia. Its concentration can be used as an indica- torof immune function in schizophrenia patients.